Top recurrent AML mutations in genes which involves in epigenetic regulations, cell signaling, transcriptional programming were selected for such analysis: NPM1, DNMT3A, FLT3, KIT, KRAS, NRAS, PTPN11, CEBPA and RUNX1. When combination of mutation was not considered, patients with mutations in KIT, NRAS, PTPN11 and CEBPA appear to be allocated in the region above the dashed line (territory of M2) (Fig. 2B; n = 7, 7, 6, 13 respectively). This evidence concerns the gene KRAS and acute myeloid leukemia.